You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3876 results
  1. A Mobile-Delivered Personalized Feedback Intervention for Black Individuals who Engage in Hazardous Drinking

    SBC: HEALTH BEHAVIOR SOLUTIONS INC            Topic: 400

    PROJECT SUMMARY/ABSTRACT Black persons are the second largest racial minority group in the United States (US) and experience striking health disparities, particularly in terms of hazardous drinking and co-occurring elevated anxiety. The co- occurrence of these risk factors contributes to worse physical/mental health outcomes among Black individuals. Few interventions to date have targeted hazardou ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Urine Test for At-Home Monitoring of Blood Phe Levels for PKU

    SBC: CIRCA BIOSCIENCE LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT This project proposes the development of technologies to provide low-cost monitoring of phenylalanine (Phe) levels in the blood by a simple, noninvasive, at-home urine test, in order to enable daily monitoring by individuals with phenylketonuria (PKU). Also known as phenylalanine hydroxylase deficiency, PKU is a rare inborn error of metabolism that occurs in the US at a fr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients

    SBC: PASCALL Systems, Incorporated            Topic: NIA

    Each day, more than 100,000 patients undergo general anesthesia in the United States. The current practice of general anesthesia is prone to over-sedating patients, either due to the lack of brain monitoring or using brain monitors with inaccurate indices. Over-sedation (at 28% incidence) contributes to perioperative neurocognitive disorders (PNDs) in elderly population (≥65yrs). The cost of PND ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Vitiligo topical treatment applying a potent, highly selective MC1R agonist

    SBC: MC1R VENTURES LLC            Topic: NIAMS

    PROJECT SUMMARY Vitiligo is the most common acquired hypopigmentary disorder that afflicts 0.5-2% of the world population, from all ethnicities and skin color. It is characterized by loss of melanocytes, which is often progressive, resulting in depigmented skin lesions. Vitiligo can be segmental (5-16% of all cases) or most commonly, non-segmental. It is a disease of young adults, as 25% of all no ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Chondrofluid for arthroscopic knee cartilage repair

    SBC: CARTILAGE INC            Topic: NIAMS

    PROJECT SUMMARY Minor injuries to articular cartilage can initiate a catabolic cascade, causing small defects to progress into larger, more symptomatic defects. Pain, lesion progression, and accelerated joint deterioration may be avoided with strategies that repair small defects with hyaline-like cartilage. The repair of chondral defects using arthroscopic techniques, performed in a minimally inva ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD

    SBC: MYOGENICA INC.            Topic: NIAMS

    PROJECT SUMMARY Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy, caused due to mutations in the dystrophin gene. DMD is characterized by progressive muscle wasting and overall loss of muscle function. DMD patients become wheel chair dependant by 12 years of age and the associated cardiorespiratory complications result in their early death around 20 years of age. Dys ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis

    SBC: Provizigen LLC            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Post-traumatic osteoarthritis (PTOA) is a degenerative disease of cartilage brought on by traumatic injury to the articular joints. Acute joint injury is followed by severe joint pain and inflammation. This results in much more rapid degeneration of cartilage than in other forms of osteoarthritis, due to the joint instability caused by trauma as well as the increase in pro ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government